A comparison of population-based cancer incidence rates in Israel and Jordan

Freedman, Laurence S.; Barchana, Micha; Al-Kayed, Sameer A.; Qasem, M.B.; Young, John L.; Edwards, Brenda K.; Ries, Lynn A. G.; Roffers, Steven D.; Harford, Joe B.; Silbermann, Michael

doi:10.1097/00008469-200310000-00003

Cited by 25 publications

(24 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number of patients with non‐Hodgkin's lymphoma (NHL) attributed to HCV was based on published data and age‐standardised incidence rates (ASR) of NHL in Egypt 10, 11, 12, 13. The age and gender distribution of NHL was obtained from the Gharbia cancer registry 14.…”

Section: Methodsmentioning

confidence: 99%

“…The age and gender distribution of NHL was obtained from the Gharbia cancer registry 14. The ASR of NHL in Egypt is 14.2/100 000,13 representing approximately 12 500 new cases annually. The proportion caused by HCV infection is 42%,13 or an estimated 4930 incident NHL cases annually.…”

Section: Methodsmentioning

confidence: 99%

“…The ASR of NHL in Egypt is 14.2/100 000,13 representing approximately 12 500 new cases annually. The proportion caused by HCV infection is 42%,13 or an estimated 4930 incident NHL cases annually. The incremental prevalence of diabetes attributable to HCV came from previously published literature 15, 16.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies

Estes

Abdel-Kareem²,

Abdel-Razek³

et al. 2015

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SummaryBackgroundThe prevalence of hepatitis C virus (HCV) infection in Egypt is the highest in the world, yet the total economic burden has not been quantified. Improved understanding of costs and the impact of treatment strategies will provide for better allocation of resources to reduce HCV disease and economic burden.AimA modelling approach was used to quantify the current HCV‐infected population, future disease progression and associated costs in Egypt.MethodsDirect healthcare costs were calculated from a nationally representative hospital and a disability adjusted life year (DALY) template was used with monetary value assigned to lost life years. Three scenarios were considered: (i) Historical treatment scenario: 50% SVR; 65 000 treated annually, (ii) Current treatment scenario: 90% sustained virologic response (SVR); 65 000 treated annually, (iii) Increased treatment scenario: 90% SVR; 325 000 treated annually by 2018.ResultsCumulative DALYs (2015–2030) under Scenario 1 were estimated at 7.88 million and cumulative costs estimated at $89.07 billion. Annual DALYs increased 16% during 2015–2030 while annual costs more than doubled. Scenario 2 reduced cumulative DALYs and costs by 7% and 4%, respectively. Under Scenario 3, total costs declined 73% to $1047 million during 2015–2030. As compared to Scenario 1, cumulative DALYs and costs decreased 37% and 35%, respectively.ConclusionsThis is the first estimate of the total economic burden of HCV in Egypt. Extraordinary measures are necessary to substantially reduce HCV disease and cost burden. With newer therapies, strategies to reduce disease burden are feasible and cost‐effective.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies

Estes

Abdel-Kareem²,

Abdel-Razek³

et al. 2015

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…12,[38][39][40] The most complete published data is from the Kingdom of Jordan and confirms the higher risk for rectal cancer in their population as compared to SEER or Israeli data. 41 A Middle East Consortium monograph, comparing malignant diseases in 5 Middle Eastern populations, 1996-2002, is now being published by the National Cancer Institute (USA). This will provide more comparative data from neighboring countries.…”

Section: Discussionmentioning

confidence: 99%

The changing incidence and sites of colorectal cancer in the Israeli Arab population and their clinical implications

Rozen

Rosner²,

Liphshitz

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

Israeli Arabs have been at low risk for colorectal cancer (CRC) and had mainly proximal cancer, but increasing CRC is now noted. We examined this trend and CRC site and compared them to the total Jewish population and to the low-risk Jews of AsianAfrican origin. Israel Cancer Registry CRC data, 1982 Arabs and Jews was computed by gender, age and site: rectal cancer included recto-sigmoid junction; ''right-sided'' CRC included the proximal colon up to and also the splenic flexure.

show abstract

“…3 Urine-based assays represent holy grail of cancer research that can detect BC non-invasively with high potential to reduce traditional procedures. 4 Recent studies suggested a crucial role of autophagyrelated genes (Atgs) and apoptosis in the development of cancer, including that of the bladder.…”

Section: Introductionmentioning

confidence: 99%

Identification and validation of a novel autophagy gene expression signature for human bladder cancer patients

et al. 2017

View full text Add to dashboard Cite

We sought to identify and validate a novel urinary autophagy transcript signature in patients with bladder cancer and evaluate its clinical utility. We performed an initial screening for seven autophagy transcript–based panel (autophagy-related protein 12 (ATG12); WD repeat domain, phosphoinositide interacting 2 (WIPI2); FYVE and coiled-coil domain-containing protein 1 (FYCO1); microtubule-associated protein light chain (MAPLC3); RB1-inducible coiled-coil 1 (RB1CC1); tachylectin-II-like beta-propeller domain 1 (TECPR1); and Unc-51-like kinase (ULK1)) that was identified based on bioinformatics analysis followed by SYBR Green–based polymerase chain reaction array validation in paired tissue and urine samples. Afterward, we evaluated the expression of differentially expressed autophagy transcripts in an independent validation set with reverse transcription quantitative real-time polymerase chain reaction in urine sediments of 140 patients with bladder cancer, 68 patients with benign urological lesions, and 74 healthy controls (age and sex matched). The expression levels of ATG12, FYCO1, TECPR1, and ULK1 in paired bladder tissue and urine samples were significantly lower in bladder cancer than in control group (p < 0.001). In the validation set, the receiver-operating characteristic curve analyses demonstrated that each urinary autophagy transcripts showed high sensitivity and specificity for distinguishing bladder cancer from non–bladder cancer patients (ATG12, 75.4% and 86.1%; FYCO1, 87% and 75.7%; ULK1, 85.5% and 75.6%; and TECPR1, 90% and 81.9%). We document and validate a novel autophagy transcript signature for human bladder cancer diagnosis: bilharzial and non-bilharzial types.

show abstract

A comparison of population-based cancer incidence rates in Israel and Jordan

Cited by 25 publications

References 5 publications

Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies

Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies

The changing incidence and sites of colorectal cancer in the Israeli Arab population and their clinical implications

Identification and validation of a novel autophagy gene expression signature for human bladder cancer patients

Contact Info

Product

Resources

About